OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
7
Results
Show all
Save search
Copy query
Show results for
Unknown
(7)
Publication Date
Release Date
2025
(1)
2024
(1)
2018
(1)
2016
(1)
2015
(1)
2012
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
Not available
S-EPMC12245952
|
biostudies-literature
Cite
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Not available
S-EPMC11409264
|
biostudies-literature
Cite
Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.
Not available
S-EPMC6004555
|
biostudies-literature
Cite
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Not available
S-EPMC3286387
|
biostudies-literature
Cite
Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial.
Not available
S-EPMC4322188
|
biostudies-literature
Cite
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
Not available
S-EPMC3386495
|
biostudies-literature
Cite
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Not available
S-EPMC4731690
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets